NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, Sandy Srinivas

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes. This report summarizes the background data presented at the task force meeting and the ensuing discussion.

Original languageEnglish (US)
Pages (from-to)S1-S29
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume9
Issue numberSUPPL. 1
StatePublished - Mar 24 2011
Externally publishedYes

Keywords

  • Molecular targeted therapy
  • NCCN
  • Patient outcomes
  • Renal cell carcinoma
  • TKI
  • VEGF
  • mTOR

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy'. Together they form a unique fingerprint.

  • Cite this

    Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., Kumar, R., Margolin, K. A., Michaelson, M. D., Motzer, R. J., Pili, R., Roethke, S., & Srinivas, S. (2011). NCCN task force report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. JNCCN Journal of the National Comprehensive Cancer Network, 9(SUPPL. 1), S1-S29.